Regulus Therapeutics Inc (RGLS)

1.32
0.01 0.75
NASDAQ : Health Care
Prev Close 1.33
Open 1.34
Day Low/High 1.26 / 1.34
52 Wk Low/High 2.44 / 10.60
Volume 889.45K
Avg Volume 821.20K
Exchange NASDAQ
Shares Outstanding 103.79M
Market Cap 135.96M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Regulus To Provide Second Quarter 2017 Financial Results On August 1, 2017

Regulus To Provide Second Quarter 2017 Financial Results On August 1, 2017

Conference Call and Webcast to Follow

Regulus Therapeutics Stock Sees Short Interest Make 14.2% Move

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 532,839 share increase in total short interest for Regulus Therapeutics Inc , to 4,283,850, an increase of 14.21% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip

After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.

Regulus Announces Pipeline Updates And Advancements

Phase II RG-012 HERA and Renal Biopsy studies for Alport syndrome move forward

RGLS: Insiders vs. Shorts

The most recent short interest data was recently released for the 04/13/2017 settlement date, and Regulus Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 6.11 "days to cover" versus the median component at 5.14. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Regulus To Provide First Quarter 2017 Financial Results On May 4, 2017

Conference Call and Webcast to Follow

Short Interest In Regulus Therapeutics Makes 11% Move

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 489,371 share increase in total short interest for Regulus Therapeutics Inc , to 4,896,011, an increase of 11.11% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Regulus Therapeutics Inc. Lead Plaintiff Deadline Of April 3, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc.

RGLS INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Regulus Therapeutics Inc. And A Lead Plaintiff Deadline Of April 3, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced A Class Action On Behalf Of Shareholders Of Regulus Therapeutics Inc. -Lead Plaintiff Deadline Of April 3, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc.

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

RGLS SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Regulus Therapeutics Inc. And A Lead Plaintiff Deadline Of April 3, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Regulus Therapeutics Inc.

Regulus To Release Fourth Quarter And Full Year 2016 Financial Results On March 2, 2017

Conference Call and Webcast to Follow

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Regulus Therapeutics Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Regulus Therapeutics Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Regulus Therapeutics Inc. - RGLS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Regulus Therapeutics Inc. - RGLS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Regulus Therapeutics Inc.

Interesting RGLS Put And Call Options For February 2017

Interesting RGLS Put And Call Options For February 2017

Investors in Regulus Therapeutics Inc saw new options begin trading this week, for the February 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Regulus Therapeutics (RGLS): Today's Weak On High Volume Stock

Regulus Therapeutics (RGLS): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a weak on high relative volume candidate

TheStreet Quant Rating: D- (Sell)